These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17987285)

  • 1. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.
    Saari TI; Laine K; Neuvonen M; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2008 Jan; 64(1):25-30. PubMed ID: 17987285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole and fluconazole increase the exposure to oral diazepam.
    Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.
    Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Vyyryläinen H; Laine K
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1967-72. PubMed ID: 16723553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voriconazole drastically increases exposure to oral oxycodone.
    Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.
    Fihlman M; Hemmilä T; Hagelberg NM; Kuusniemi K; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1363-1371. PubMed ID: 27510521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
    Ibrahim AE; Feldman J; Karim A; Kharasch ED
    Anesthesiology; 2003 Apr; 98(4):853-61. PubMed ID: 12657846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole greatly increases the exposure to oral buprenorphine.
    Fihlman M; Hemmilä T; Hagelberg NM; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1615-1622. PubMed ID: 30167757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Apr; 79(4):362-70. PubMed ID: 16580904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of voriconazole on the pharmacokinetics of diclofenac.
    Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Laine K
    Fundam Clin Pharmacol; 2007 Dec; 21(6):651-6. PubMed ID: 18034666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
    Kharasch ED; Whittington D; Hoffer C
    Anesthesiology; 2004 Sep; 101(3):729-37. PubMed ID: 15329598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles.
    Yamazaki H; Nakamoto M; Shimizu M; Murayama N; Niwa T
    Br J Clin Pharmacol; 2010 Jun; 69(6):593-7. PubMed ID: 20565450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.
    Olkkola KT; Palkama VJ; Neuvonen PJ
    Anesthesiology; 1999 Sep; 91(3):681-5. PubMed ID: 10485779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.
    Barry AL; Brown SD
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1948-9. PubMed ID: 8843312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
    Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.
    Burn AK; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; McCarthy DI; Rinaldi MG; Redding SW
    J Clin Microbiol; 2004 Dec; 42(12):5846-8. PubMed ID: 15583322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
    Andes D; Marchillo K; Stamstad T; Conklin R
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3165-9. PubMed ID: 14506026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.